Qurient Co., Ltd. (KOSDAQ:115180)

Market Cap	1.08T +196.4%
Revenue (ttm)	6.98B -23.9%
Net Income	-30.12B
EPS	-880.12
Shares Out	40.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214,699
Average Volume	198,157
Open	26,250
Previous Close	26,800
Day's Range	25,000 - 27,650
52-Week Range	9,400 - 62,900
Beta	0.51
RSI	27.45
Earnings Date	May 19, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115180

Financial Performance

In 2025, Qurient's revenue was 6.98 billion, a decrease of -23.94% compared to the previous year's 9.18 billion. Losses were -30.12 billion, 24.9% more than in 2024.